Health Condition 1: N19- Unspecified kidney failure
Conditions
Interventions
Intervention1: Desmopressin acetate 3 mcg/kg intranasal + tranexamic acid 500 mg IV: Patients will be randomized into experimental and control groups using block randomization by an investigator not i
Sponsors
Dr RAJESH JHORAWAT
Eligibility
Inclusion criteria
Inclusion criteria: Patients undergoing kidney biopsy with reduced renal function eGFR less than 60 ml per min per 1.73 m2 BSA with the following characteristics Age greater than or equal to 18 years Normal coagulation profile PT INR less than 1.2 times control Platelets greater than 100000 per mm3 BP controlled to less than 140 by 90 mmHg
Exclusion criteria
Exclusion criteria: Patients with the following will be excluded from the study EGFR greater than 60 ml per min per 1.73 m2 BSA Renal cell carcinoma Hydro pyonephrosis Significantly decreased kidney size on ultrasound image Patients with known cardiac disease or a history of thrombotic events in the past Morbid obesity BMI greater than or equal to 40 kg per m2 Patients undergoing transplant kidney biopsy Pregnant patients Serum sodium less than 130 mEq per L Patients with coagulopathy Uncontrolled sepsis Solitary kidney
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the incidence of post-biopsy bleeding complications (major and minor) between patients receiving desmopressin plus tranexamic acid and placebo. Minor complications include perirenal hematoma and gross hematuria resolving spontaneously. Major complications include AV fistula, renal obstruction, hemoglobin drop requiring transfusion, angiography, embolization, or death.Timepoint: At baseline, 6 and 24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Assess hematoma size & hemoglobin change. 2. Identify bleeding predictors. 3. To evaluate the safety of combined therapy by monitoring adverse events, including hyponatremia & thromboembolic complications. 4. To assess procedural outcomes by comparing hospital stay duration & the need for additional interventions between the two groups. Timepoint: At baseline,6 & 24 hours | — |
Countries
India
Contacts
Public ContactDr RAJESH JHORAWAT
All India Institute of Medical Sciences Jodhpur
Outcome results
None listed